Anteris Technologies Global (NASDAQ:AVR) Shares Down 5.8% – Time to Sell?

Anteris Technologies Global Corp. (NASDAQ:AVR)’s stock price traded down 5.8% during trading on Monday . The stock traded as low as $5.21 and last traded at $5.18. 362,403 shares changed hands during trading, a decline of 71% from the average session volume of 1,267,437 shares. The stock had previously closed at $5.50.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AVR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anteris Technologies Global in a research note on Monday, December 29th. Lake Street Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Friday, January 23rd. Wells Fargo & Company began coverage on Anteris Technologies Global in a report on Wednesday, March 11th. They set an “overweight” rating and a $16.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research note on Friday, March 27th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Anteris Technologies Global has a consensus rating of “Moderate Buy” and an average target price of $15.33.

Anteris Technologies Global Stock Performance

The company’s 50 day simple moving average is $5.91 and its 200 day simple moving average is $5.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.73 and a current ratio of 0.73. The stock has a market cap of $504.92 million, a PE ratio of -2.03 and a beta of 1.58.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.75) EPS for the quarter. Anteris Technologies Global had a negative return on equity of 536.04% and a negative net margin of 4,921.27%.The business had revenue of $0.31 million for the quarter. Analysts expect that Anteris Technologies Global Corp. will post -2.66 earnings per share for the current year.

Insider Activity at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd purchased 5,000,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were bought at an average cost of $5.75 per share, with a total value of $28,750,000.00. Following the acquisition, the insider owned 13,219,814 shares of the company’s stock, valued at $76,013,930.50. This represents a 60.83% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.50% of the stock is owned by insiders.

Institutional Trading of Anteris Technologies Global

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in Anteris Technologies Global by 32.7% in the third quarter. JPMorgan Chase & Co. now owns 1,417,627 shares of the company’s stock valued at $6,379,000 after acquiring an additional 349,299 shares during the last quarter. Marex Group plc purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth approximately $641,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Anteris Technologies Global by 34.4% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,780 shares of the company’s stock worth $71,000 after purchasing an additional 4,036 shares during the period. Intech Investment Management LLC purchased a new position in Anteris Technologies Global in the fourth quarter valued at approximately $67,000. Finally, Bank of America Corp DE lifted its stake in Anteris Technologies Global by 35.7% in the third quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock valued at $48,000 after purchasing an additional 2,798 shares during the last quarter.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.